Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of SGLT2 inhibition on coronary microvascular function in type 2 diabetes
2017-000240-17Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM) and Coronary Small Vessel Disease (CMD), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Changes in coronary flow velocity reserve (CFVR). Started Feb 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on 2017-000240-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000240-17.